Marina Temkin
Since launching its formal LP effort in 2016, Boulder, Colorado-based Foundry Group firm has backed dozens of emerging managers. These relationships have also helped the firm zero in on direct investments.
Investor interest in edtech is expected to continue in a post-pandemic world, according to Tory Patterson of edtech-focused Owl Ventures, who says that we will soon see some good IPO candidates.
LPs’ fears of large markdowns in VC assets did not materialize. Valuations through Q2 are expected to either stay relatively flat or even increase, especially for late-stage focused managers.
Boston-based HLM Venture Partners has an extensive history in the sector and is currently raising its fifth $125m fund.
The Silicon Valley veteran talks about his investment in Rigetti and why he says there is a lot of excitement regarding the nascent field of quantum computing.
In 2016, the LP formed a dedicated early-stage venture capital fund by leveraging its existing VC program. It continues to re-up with long-term partners as it also adds one or two new GPs a year.
The private markets advisory firm believes the pandemic has created even greater investment opportunities in the late-stage and growth equity sectors.
Appetite for biopharma is on the rise as investors want to back scientific advances and the recession-proof sector, and generalist VCs don’t want to miss out on potential outsized returns.
The online provider of personal healthcare will likely not be doing a reverse merger with a SPAC soon, according to a venture source.
VC investment in biopharma and health tech continues to soar amid the covid-19 pandemic.